Key Highlights

  • Rocket Pharmaceuticals received FDA accelerated approval for KRESLADI, a gene therapy designed to treat severe leukocyte adhesion deficiency-I (LAD-I) in pediatric patients.
  • Shares of RCKT climbed up to 9% during premarket hours and maintained approximately 6% gains by Friday’s opening bell.
  • This marks the inaugural FDA-approved gene therapy specifically targeting severe LAD-I, a rare immune disorder affecting children with life-threatening complications.
  • Rocket received a Rare Pediatric Disease Priority Review Voucher from the FDA, which the biotech intends to sell for additional revenue.
  • The regulatory green light arrived after the company resubmitted its application following a June 2024 rejection requesting supplementary data.

Rocket Pharmaceuticals received FDA clearance for its gene therapy KRESLADI on Friday, propelling RCKT shares upward by as much as 9% during premarket hours before stabilizing at approximately 6% gains at market open.


RCKT Stock Card
Rocket Pharmaceuticals, Inc., RCKT

The regulatory clearance came through the accelerated pathway, meaning the FDA based its decision on preliminary evidence — particularly improved neutrophil CD18 and CD11a surface expression. Complete verification of therapeutic effectiveness will require additional long-term data collection through an active clinical study and a post-approval registry program.

KRESLADI, scientifically termed marnetegragene autotemce, represents an autologous hematopoietic stem cell-based gene therapy. The treatment received approval for pediatric patients diagnosed with severe LAD-I resulting from biallelic variants in the ITGB2 gene, specifically those lacking access to an HLA-matched sibling donor for stem cell transplantation.

LAD-I qualifies as an ultra-rare genetic immunodeficiency disorder. The condition triggers repeated infections and presents elevated early-childhood mortality rates when left untreated. Across the United States, prevalence estimates range from approximately one case per 100,000 to one per 200,000 live births, with severe classification applying to roughly two-thirds of diagnosed cases.

KRESLADI now stands as the inaugural FDA-approved gene therapy addressing this medical condition.

The approval journey encountered obstacles along the way. During June 2024, the FDA declined the biologics license application, requesting Rocket provide additional supporting data before completing the regulatory review process.

Rocket submitted the revised BLA, which the FDA accepted during October 2024, establishing March 28, 2026 as the target decision date — a timeline the regulatory agency honored.

Rare Pediatric Disease Voucher Provides Financial Benefit

Alongside the therapeutic approval, the FDA awarded Rocket a Rare Pediatric Disease Priority Review Voucher. Pharmaceutical companies frequently purchase these vouchers for hundreds of millions of dollars, representing a substantial financial advantage beyond the approval itself.

Rocket announced plans to explore opportunities for monetizing the voucher to enhance its financial position.

“The approval of KRESLADI represents an important milestone for the severe LAD-I community,” said CEO Gaurav Shah.

Scientific Foundation Behind the Development

The California Institute for Regenerative Medicine provided partial funding for research supporting KRESLADI’s development. The therapy addresses the ITGB2 gene, which produces a protein critical for enabling white blood cells to combat infections.

The Cranbury, New Jersey-headquartered biotech company has pursued this approval over multiple years.

The FDA established March 28, 2026 as the action date for the resubmitted BLA, and the regulatory body delivered approval precisely on the scheduled timeline.